LYAR

Across TCGA pan-cancer cohorts, LYAR mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of LYAR’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where LYAR mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types LYAR is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, COAD, and HNSC are the cancer types where LYAR tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LYAR mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	IV	+0.794	<.001	12	view →
COAD	Male	III,IV	+0.748	<.001	11	view →
HNSC	Male	III,IV	+0.366	<.001	11	view →
LSCC	Male	All	+0.333	<.001	7	view →
LUAD	Male	All	+0.191	<.001	6	view →
PDAC	Male	II,III,IV	−0.286	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

LYAR–CCRCC

Open the CCRCC breakdown →